Academic Journal
Q1Lancet HIV
About Lancet HIV
Lancet HIV is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 4.757 and an H-index of 101.
Its listed coverage is 2014-2026 and its research categories include Epidemiology (Q1); Immunology (Q1); Infectious Diseases (Q1); Virology (Q1). The 2025 dataset reports 170 documents and 2696 citations across the latest three-year reporting window.
About The Lancet HIV – Leading Global Insights on HIV Research and Treatment
The Lancet HIV is a prestigious peer-reviewed medical journal dedicated to advancing global knowledge and understanding of HIV/AIDS. Launched in 2014 as part of The Lancet family of journals, it has quickly become a trusted and influential platform for cutting-edge research, clinical practice, public health policies, and innovative approaches to HIV prevention, diagnosis, treatment, and care.
Published by Elsevier, The Lancet HIV focuses exclusively on high-quality, original research and comprehensive reviews across all aspects of HIV and AIDS. The journal covers a wide range of topics, including epidemiology, clinical trials, vaccine development, antiretroviral therapy (ART), HIV co-infections (such as tuberculosis and hepatitis), and the social determinants of HIV health outcomes.
Trusted Source for HIV Research and Evidence-Based Medicine
As one of the world’s leading journals in the field of infectious diseases, The Lancet HIV plays a critical role in shaping global HIV strategies. It is indexed in major databases like PubMed, Scopus, and Web of Science, making it highly accessible to researchers, clinicians, policymakers, and public health professionals worldwide.
The journal features contributions from leading experts in virology, immunology, sexual health, and global health. It is known for its rigorous peer-review process and commitment to publishing research that meets the highest standards of scientific integrity and ethical responsibility.
Key Features of The Lancet HIV
-
Open Access Options: Many articles are available under open access, allowing broader dissemination of knowledge and findings.
-
Monthly Issues: The journal is published monthly, ensuring a steady stream of current and relevant information.
-
Global Perspective: The Lancet HIV places strong emphasis on research from both high-income and low- and middle-income countries, reflecting the global nature of the HIV epidemic.
-
Multidisciplinary Approach: Topics covered extend beyond clinical care to include behavioral science, health systems, social justice, and community engagement in HIV care.
Impact and Importance
With a high impact factor, The Lancet HIV is among the most influential journals in the field of HIV/AIDS. Its articles frequently inform WHO guidelines, national treatment protocols, and funding strategies from organizations like UNAIDS, PEPFAR, and the Global Fund.
By promoting open scientific dialogue and highlighting emerging challenges—such as HIV drug resistance, stigma, and health disparities—The Lancet HIV helps shape the future of HIV prevention and treatment strategies worldwide.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope of The Lancet HIV: A Comprehensive Overview
The Lancet HIV is a highly respected peer-reviewed journal that focuses on the latest research, clinical practices, and advancements in the field of HIV/AIDS. It is part of The Lancet family, a globally recognized medical journal that has been at the forefront of scientific publications for over 180 years. The Lancet HIV specifically provides an in-depth platform for the exploration of topics related to HIV prevention, treatment, epidemiology, and policy. This scope makes it an invaluable resource for researchers, clinicians, and policymakers working within the field of HIV/AIDS care.
Focus Areas of The Lancet HIV
The primary goal of The Lancet HIV is to publish cutting-edge research that significantly advances our understanding of HIV. The journal's scope includes a broad range of topics, including but not limited to:
-
HIV Prevention and Treatment
The journal is committed to presenting innovative strategies and clinical trials aimed at improving HIV prevention and treatment. This includes novel antiretroviral therapies, PrEP (pre-exposure prophylaxis), and the exploration of vaccine development. Additionally, The Lancet HIV covers advancements in treatment regimens, personalized medicine, and long-acting therapies that may improve the quality of life for people living with HIV. -
Global Epidemiology of HIV
A major focus of The Lancet HIV is understanding the global burden of HIV and the factors that influence its spread. The journal publishes studies on the epidemiology of HIV in different regions of the world, examining how social, economic, and cultural factors impact HIV transmission. Key topics include high-risk populations, HIV prevalence in sub-Saharan Africa, and the effects of socio-economic disparities on HIV-related health outcomes. -
HIV and Co-infections
Individuals living with HIV are often susceptible to other infectious diseases, such as tuberculosis and viral hepatitis. The Lancet HIV explores the intersection of HIV and co-infections, providing critical insights into how co-morbidities affect HIV progression and treatment. This area of research is crucial for developing comprehensive care models for HIV-positive individuals. -
HIV and Human Rights
The social dimensions of HIV are increasingly acknowledged, and The Lancet HIV addresses the intersection of HIV with human rights, stigma, and discrimination. The journal highlights the need for equitable access to care, as well as policy solutions to protect marginalized populations, such as sex workers, people who inject drugs, and men who have sex with men. Research on the impact of HIV criminalization laws and advocacy for supportive legal frameworks are integral parts of this focus. -
Innovative Research and Technology
Advances in technology and novel research methodologies also find a place in The Lancet HIV. From genomic studies to data analytics, the journal encourages research that integrates new technologies to better understand HIV dynamics, improve diagnostics, and enhance treatment outcomes. This includes the role of artificial intelligence and machine learning in predicting HIV progression and treatment responses. -
Policy and Global Health
The Lancet HIV plays an important role in shaping global health policy by publishing evidence-based recommendations and discussing the political and economic challenges in tackling the HIV epidemic. The journal advocates for global health policies that prioritize HIV prevention and treatment, promote international collaboration, and address the disparities that exist in healthcare systems worldwide.
Recent Research Articles
Latest publications matched automatically by ISSN.
Social sciences at the centre of HIV stigma reduction
Cristian Ortega, Alemka Tomicic
2026-09 · DOI: 10.1016/s2352-3018(26)00223-7Interventions to improve viral suppression and adherence to antiretroviral therapy among people living with HIV: a systematic review and network meta-analysis
Steve Kanters, David S Lawrence, Vanessa S McLennan, Catherine Orrell et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00119-0Achieving 95-95-95 outcomes: it takes a couple
Nora E Rosenberg, Olivia R Gonzalez, Cheryl C Johnson
2026-09 · DOI: 10.1016/s2352-3018(26)00122-0Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa
Kim Steegen, Jeremy Nel, Erin H Smeijsters, Chijioke N Umunnakwe et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00144-xAdvancing a fixed-dose combination for children with HIV
Sharon Nachman
2026-09 · DOI: 10.1016/s2352-3018(26)00199-2Invisible populations: SOGI data and HIV drug safety
Lauren B Beach, Benjamin Young, Craig Davenport, Kemi Williams et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00143-8Occupational HIV monitoring should match standard of care
Matthew Kneale
2026-09 · DOI: 10.1016/s2352-3018(26)00200-6Uganda integrates HIV care into general medical services
Roger Pebody
2026-09 · DOI: 10.1016/s2352-3018(26)00113-xEvolving understanding of Kaposi sarcoma and associated diseases in the ART era
Nazzarena Labo, Elena M Cornejo Castro, Vickie A Marshall, Fahmida Shaik et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00110-4HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial
Linda-Gail Bekker, Dhayendre Moodley, Dazon Dixon Diallo, Ishana Harkoo et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00112-8Targeted point-of-care HIV testing at birth for newborns at high risk of vertical transmission in Botswana: a prospective cohort study
Gbolahan Ajibola, Sean Brummel, Terence Mohammed, Maureen Sakoi-Mosetlhi et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00176-1Does U=U apply during breastfeeding? An urgent research priority
Dvora Joseph Davey, Shahin Lockman, Roger Shapiro, Thokozile Malaba et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00167-0Will the new UN political declaration deliver?
The Lancet HIV
2026-09 · DOI: 10.1016/s2352-3018(26)00205-5Effectiveness of interventions to promote couples-based HIV testing and family health during pregnancy and postpartum in Kenya: a multicentre, couples-based, randomised controlled trial
Janet M Turan, Zachary A Kwena, Kevin Owuor, Anna Helova et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00104-9Low-level viraemia in children living with HIV
Bianca Alvarez, Patricia Agaba, Rosemary Mrina, Meagan Stephenson et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00224-9Highlights of AIDS 2026
Adrian Gonzalez Lopez
2026-09 · DOI: 10.1016/s2352-3018(26)00203-1Cost-effectiveness of emergency department opt-out testing for HIV in England: a modelling study
Josephine G Walker, Rebecca F Baggaley, Gareth Myring, Michael A Irvine et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00109-8Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial
Anne E M Kamphuis, Nicolas Salvadori, Hilda Angela Mujuru, Mutsawashe Bwakura-Dangarembizi et al.
2026-09 · DOI: 10.1016/s2352-3018(26)00168-2National and regional analysis of HIV transmission dynamics in Morocco: a mathematical modelling study
Hiam Chemaitelly, Ibtissam Khoudri, Amina El Kettani, Meriem Ghannam et al.
2026-08 · DOI: 10.1016/s2352-3018(26)00054-8Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Cécile Tremblay, Innocent Valea, Birahim Pierre Ndiaye, Houreratou Barry et al.
2026-08 · DOI: 10.1016/s2352-3018(26)00118-9Reviews
Community Reviews
Version History
April 22, 2025 at 5:15 am
April 22, 2025